Search results

Filters
Close
ADDED DATE
Added date
AUTHOR Please select
TOPICS Please select
WATCH / LISTEN / READ TIME
Author(s): Gabriele Fragasso Added: 3 years ago
The development of heart failure is rarely dependent on primary alterations of cardiac metabolism. The majority of heart failure cases result from diseases of the cardiac muscle, most frequently ischaemic heart disease. However, whatever the cause of heart failure, the net result will be depletion of myocardial adenosine triphosphate (ATP), phosphocreatine and creatine kinase levels with… View more

Heart Failure
Calming the Nervous Heart: Autonomic Therapies in Heart Failure
Author(s): Peter Hanna , Kalyanam Shivkumar , Jeffrey L Ardell Added: 3 years ago
Heart failure (HF) is associated with significant morbidity and mortality, and the burden of disease is rising.1 Despite improved survival – partly a result of advances in medical therapy, coronary interventions and ICD – the mortality rate remains high and relatively stagnant.2 Moreover, advanced HF is associated with impaired quality of life (QOL), which is reflected in the significant number… View more

Heart Failure
Author(s): Thomas G von Lueder , Dipak Kotecha , Dan Atar , et al Added: 3 years ago
Heart Failure (HF) constitutes a major global health problem, evidenced by substantial morbidity and mortality, requiring enormous healthcare-related expenditure. HF is associated with high symptomatic burden, and with a relentless and progressive clinical course towards end-stage disease. A large body of epidemiological data suggests that the prognosis in HF is as poor as in advanced cancer.1… View more

Heart Failure
Inotropes in Acute Heart Failure: From Guidelines to Practical Use: Therapeutic Options and Clinical Practice
Author(s): Vasiliki Bistola , Angelos Arfaras-Melainis , Eftihia Polyzogopoulou , et al Added: 3 years ago
Acute heart failure (AHF) is defined as the sudden presentation or sudden aggravation of signs and symptoms of heart failure, often requiring hospitalisation.1 It is a life-threatening condition, with in-hospital mortality ranging from 22% to 37% in severe cases of cardiogenic shock.2–4 Inotropes have been used in the management of patients with AHF for decades, especially for patients with… View more

Heart Failure
Author(s): Ovidiu Chioncel , Sean P Collins , Andrew P Ambrosy , et al Added: 3 years ago
Acute heart failure (AHF) is a heterogeneous clinical syndrome including diverse phenotypes sharing similar presenting signs and symptoms.1 The diversity of aetiologies and precipitants of HF and their specific pathophysiologic mechanisms, may result in distinct clinical profiles requiring specific treatment approaches. Pulmonary oedema (PO) is a common manifestation of AHF associated with a… View more

Heart Failure
Author(s): Juan Tamargo Added: 3 years ago
Chronic heart failure (HF) is a complex and progressive clinical syndrome resulting from any abnormality of cardiac structure or function. The American College of Cardiology Foundation/American Heart Association guideline defines HF as ‘a complex clinical syndrome that results from any structural or functional impairment of ventricular filling or ejection of blood’.1 The European Society of… View more

Heart Failure
Levosimendan Efficacy and Safety: 20 years of SIMDAX in Clinical Use
Author(s): Zoltán Papp , Piergiuseppe Agostoni , Julian Alvarez , et al Added: 3 years ago
Origins of a Unique Cardiovascular Agent Before the 1980s, therapy to enhance cardiac contractility in heart failure (HF) substantially meant oral digitalis glycosides, supplemented by beta-adrenergic agonists such as dopamine or dobutamine (introduced in the middle of the 1970s) in acute situations.1 It was therefore a matter of some note when the US Food and Drug Administration approved a new… View more

Heart Failure
Haemodynamic Balance in Acute and Advanced Heart Failure: An Expert Perspective on the Role of Levosimendan
Author(s): Piergiuseppe Agostoni , Dimitrios T Farmakis , Jose M García-Pinilla , et al Added: 3 years ago
The use of IV vasoactive drugs, diuretics, vasodilators and inotropes for correcting haemodynamic dysfunction in patients with decompensated heart failure has been described over many decades.1 However, data on their effects on prognosis do not offer a convincing picture of clinical benefit.2 This is particularly true regarding IV inotropes. Clinical data collected on the effects of cardiac… View more

Heart Failure
Foreword

Article

Author(s): Andrew JS Coats , Giuseppe Rosano Added: 3 years ago
It is with great pleasure that we introduce to you to this issue of Cardiac Failure Review. In this issue, we focus on clinical practice research and observations in advanced heart failure, a topic of increasing interest to triallists, innovators and practising physicians alike. We know the prognosis and outlook remains poor for advanced heart failure, especially if the patient is unlikely… View more

Heart Failure
Foreword

Article

Author(s): Andrew JS Coats , Giuseppe Rosano Added: 3 years ago
It is with great pleasure that we introduce to you, our readers, Volume 4.2 of Cardiac Failure Review. Heart failure with mid-range ejection fraction, HFmrEF, formally introduced into the definition of heart failure phenotypes by the 2016 ESC Heart Failure Guidelines,1 has been the subject of intense investigation and analysis since its launch as a concept. One of these outcomes has been the re… View more

Heart Failure